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institution was $3,495,887 (322,350 USD). Sensitivity analysis
for the worst scenario (3% of metronidazol prescriptions, 96%
unjustiﬁed prescriptions and a higher unit price) would lead to
an annual cost of $5,193,064 (478,844 USD). CONCLUSIONS:
Inadequate prescribing criteria persists for metronidazol despite
of clinical criteria and published evidences. Our study showed
that there is a gap between medical practice and clinical and
health economics research. There is also an opportunity to
update clinicians’ knowledge using educational strategies.
Another challenge is to educate patients in the sense that drugs
prescription is not always the best option but hygiene, good 
sanitary conditions and nutrition, and prevention. Finally the
opportunity cost of unjustiﬁed prescriptions should not be
underestimated but more often evaluated and taken into account
for policies.
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OBJECTIVE: HIV treatment has involved infectious disease 
specialists and other specialties. We studied the relative use of
phenotypic resistance testing among specialties and by different
regions in the U.S over time. METHODS: Phenotypic resistance
testing data from Virologic was aggregated for 7/01 ¨C 6/03.
Tests were assigned to each ordering physicians. Self-reported
specialty was identiﬁed and an automated sample generated. Spe-
cialties were grouped as infectious disease, internal medicine,
primary care (family practice & general practice) and all others.
“Unspeciﬁed” physician records were deleted. Data were ana-
lyzed for statistically signiﬁcant differences in: the average use of
resistance testing by each specialty in July 2001–June 2002 com-
pared to July 2002–June 2003 across the US, and the use of resis-
tance testing in the each US census region compared to the
average US-wide use for each respective specialty. RESULTS:
There were approximately 2600 physicians in the sample for
which 250,000 drug resistance tests were conducted. It showed
across the US the average use of phenotypic resistance testing by
Infectious Disease statistically increased 5% (p ≥ 0.05) for July
2002–June 2003 compared to July 2001–June 2002 and the use
by other specialties decreased. Within each specialty there were
statistically signiﬁcant differences by geographic region in the use
of phenotypic resistance testing. CONCLUSION: Based on its
relative ease of interpretation compared to genotypic informa-
tion we might have predicted that the use of phenotypic 
resistance testing would increase for non-Infectious Disease spe-
cialists. The reverse was true i.e. it increased for Infectious
Disease relative to other specialties use. Signiﬁcant differences in
the use of phenotypic resistance testing were also seen by regions.
Contributing factors may include increasing adoption of pheno-
typic resistance testing by Infectious Disease specialists, variation
in patient severity and ﬁnancial constraints.
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OBJECTIVE: The intravenous piperacillin/tazobactam antibiotic
combination product does not currently carry an indication for
pediatric use in the United States. Despite the lack of established
pediatric safety data in the US, piperacillin/tazobactam is com-
monly prescribed for the treatment of infectious diseases in this
population. This study examines the safety of intravenous (IV)
piperacillin/tazobactam prescribed off-label to hospitalized pedi-
atric patients. METHODS: This protocol is an on-going (>2
years duration) observational study evaluating off-label medica-
tion usage in the pediatric population. The pharmacy order entry
system, containing all medications prescribed to a patient during
hospitalization, is examined on a twice-weekly basis to identify
patients admitted to a general pediatric unit who receive off-label
IV piperacillin/tazobactam. Charts of identiﬁed patients are then
reviewed to determine applicable medical history and outcomes
of piperacillin/tazobactam use. RESULTS: Forty-three courses of
IV piperacillin/tazobactam were administered to 39 pediatric
patients ranging in age from 5 months to 18 years (mean + SD
9.7 + 5.7 years). The mean weight of the patients was 29.2kg
(range 6.5 to 70.3g). The average dose and duration of
piperacillin/tazobactam therapy was 9.6g/day (range 1.8 to 18
g) and 6.4 days (1 to 20 days), respectively. Of the 43 pediatric
observations, no adverse drug events were reported resulting
from piperacillin/tazobactam administration. CONCLUSIONS:
Availability of combination antibiotic medications approved for
use in hospitalized pediatric patients is limited. Based on the
small number of patients in this review, off-label use of
piperacillin/tazobactam appears to be a safe selection in the 
management of infectious disease in a general hospital pediatric
unit. However, further investigation involving larger pediatric
populations is required to establish the true safety of
piperacillin/tazobactam in hospitalized pediatric patients.
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OBJECTIVES: Chronic hepatitis C is a major public health
problem whose incidence is expected to increase. But, treatments
are available that can eliminate the virus in about 50% of cases.
The purposes of this research were to: examine the prevalence
in the Louisiana Medicaid population, determine testing rates
and follow-up physician visits in at-risk populations and
examine treatment of hepatitis C. METHODS: The was a ret-
rospective analysis of Louisiana Medicaid medical and pharmacy
claims. RESULTS: The 3-year prevalence of hepatitis C as deter-
mined by a primary or secondary diagnosis was 7.08 per 1000.
Of those diagnosed from 1998–2000, 35% were age 41–50;
31%, age 21–40; and 23%, age 51–64. Of the 25,788 recipients
who were tested for hepatitis C in the 3-year period, the highest
testing rate in at-risk groups was among those with hepatitis B
with almost 73% having had a hepatitis C test. Other at-risk
groups were not tested at that rate. Of the 25,788 tested for
hepatitis C, 17,385 received follow-up care (an outpatient 
physician visit within 90 days of the test). Of those who were
tested, 643 received a diagnosis of hepatitis C with 489 (76%)
receiving treatment. Of those treated, 364 (74.44%) started on
monotherapy and 125 (25.56%) started on combination therapy.
Switches from monotherapy to combination therapy were
common. After 6 months, 132 had switched to combination
therapy and 204 had switched by 12 months. Of those diagnosed
with cirrhosis, 88.07% also had a diagnosis of hepatitis C. Of
recipients with other advanced liver disease, 53.47% had a
hepatitis C diagnosis. CONCLUSIONS: There is a high preva-
lence of hepatitis C in the Louisiana Medicaid program. Many
at risk-recipients are not being tested. Of those tested, most
received follow up care and most diagnosed with hepatitis C
were receiving treatment.
